Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7798 in healthy subjects and Crohn's disease patients
NCT05452304Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of azd7798 in Crohn's disease (16 arms), sponsored by AstraZeneca. Primary endpoint: Adverse Events at 85 days. Started Jul 2022; status: completed.
02
Drugs
azd7798
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05452304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05452304.